Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

IL-12/23 inhibitors

5 evidence topics · 5 sources

Ustekinumab: Ps STUDY 1 and Ps STUDY 2 outcomes at week 12
Outcome at Week 12, n (%)Ps STUDY 1 placebo (N=255)Ps STUDY 1 STELARA 45 mg (N=255)Ps STUDY 1 STELARA 90 mg (N=256)Ps STUDY 2 placebo (N=410)Ps STUDY 2 STELARA 45 mg (N=409)Ps STUDY 2 STELARA 90 mg (N=411)
PASI 75 response“8 (3%)”“171 (67%)”“170 (66%)”“15 (4%)”“273 (67%)”“311 (76%)”
PGA of cleared or minimal“10 (4%)”“151 (59%)”“156 (61%)”“18 (4%)”“277 (68%)”“300 (73%)”
Decision aid: ustekinumab
AgentRoughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months?What is the likelihood of staying on this treatment for more than 1 year?
Ustekinumab“34%”“84–86% chance”
Network meta-analysis: ustekinumab compared with other biologics and oral agents
TreatmentPASI 75 at 10 to 16 weeks, % (95% CrI)PASI 90 at 10 to 16 weeks, % (95% CrI)PASI 100 at 10 to 16 weeks, % (95% CrI)
Ustekinumab, 45 mg ≤100 kg, 90 mg >100 kg“69.7 (66.3-73.1)”View highlighted excerpt for this quote“43.9 (40.2-47.9)”View highlighted excerpt for this quote“16.7 (14.4-19.3)”View highlighted excerpt for this quote